



RECEIVED 42  
PATENT APPLICATION  
MAY 23 2001

Applicant(s): Amgen

Serial No.: 09/389,545

Group Art Unit No.: 1642

Filed: September 3, 1999

Examiner: Tedeschi, B.

For: Compositions and Methods for the Prevention or  
Treatment of Cancer and Bone Loss Associated with  
Cancer

Docket No.: A-605

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:


Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicants by the undersigned attorney/agent, certifies that each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months pursuant to 37 C.F.R. 1.97(e)(1) prior to the filing of this statement.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,



Robert B. Winter  
Attorney/Agent for Applicant(s)  
Registration No.: 34,458  
Phone: (805) 447-2425  
Date: *MAY 15, 2001*

Please send all future correspondence to:

U.S. Patent Operations/RBW  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

#### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

*May 16, 2001*

Date

*D. Dillon*

Signature